#ICYMI, we presented 3-year follow-up data at #KCRS25. Renal cell carcinoma (#RCC) is the most common type of #kidneycancer and we’re proud to have shared research in this oral presentation to help patients facing this challenging disease. At Eisai, we remain deeply committed to advancing innovative cancer research and are grateful to the patients and researchers who help us contribute to the ongoing dialogue. https://xmrrwallet.com/cmx.pbit.ly/4lWQxa7 #Oncology
Felix Perez, CEO Research Director
1wImpressive work by Eisai US in advancing cancer research! Sharing 3-year follow-up data in RCC at #KCRS25 reflects a strong commitment to improving outcomes for patients facing kidney cancer. Grateful to the teams and patients driving this progress. #Oncology #RCC #KidneyCancer